Future of Chronic Hepatitis B Infection Therapies

This publication has 9 references indexed in Scilit:

• Safety, Tolerability, and Pharmacokinetics of a Novel Human Hepatitis B Virus Capsid Assembly Modulator Canocapavir: A Randomized First-in-Human Study
  Gastro Hep Advances, 2023
• Nomenclature of HBV core protein-targeting antivirals
  Nature Reviews Gastroenterology & Hepatology, 2022
• Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B
  Hepatology Communications, 2022
• Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB
  Journal of Hepatology, 2022
• Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy
  Journal of Hepatology, 2022
• Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B
  Current Hepatology Reports, 2020
• Pegylated interferon alfa for chronic hepatitis B: systematic review and meta‐analysis
  Journal of Viral Hepatitis, 2015
• HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
  Gut, 2013
• Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B*
  Journal of Viral Hepatitis, 2010